AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02407223
Drug: Group 3: Ustekinumab 90 mg
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive ustekinumab 90 mg subcutaneously at Weeks 0 and 4, followed by every four weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and Week 52 will receive either placebo or ustekinumab 90 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or Week 52 will continue receiving ustekinumab 90 mg every 12 weeks through Week 88.
Trial: NCT00310011
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00310011
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00310011
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02999477
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be administered in clinic every three weeks.
Trial: NCT02999477
Drug: Nab-Paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-Paclitaxel will be administered in clinic every week.
Trial: NCT01827787
Drug: Eribulin
RxNorm normalized name: Eribulin
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00861549
Drug: Phencynonate hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Levophencynonate (DB16011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2mg/tablet
Trial: NCT00050375
Drug: oregovomab
RxNorm normalized name: Oregovomab
DrugBank: Oregovomab (DB04964)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02743078
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg/kg every 2 weeks intravenously over 30 minutes.
Trial: NCT02492178
Drug: Intrarectal artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02492178
Drug: Intravenous artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02492178
Drug: Intravenous quinine
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03553758
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects' brain waves will be monitored by EEG recording under ketamine general anesthesia over the course of approximately 60 minutes. Patients pain and dissociation will be assessed before the induction of ketamine and periodically after. Approximately 1 hour after ketamine induction, Midazolam will be administered to reduce patient dissociation.
Trial: NCT02515838
Drug: Sevuparin
RxNorm normalized name: Sevuparin
DrugBank: Sevuparin (DB15007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Drug Product sevuparin solution for IV infusion
Trial: NCT03823534
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: morphine IV PRN (or other opioid) for severe breakthrough pain
Trial: NCT03823534
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Upon discharge, patients will be prescribed the equivalent of 1-2 hydrocodone 5mg Q4 hours upon should they have preexisting liver disease and are unable to consume acetaminophen.
Trial: NCT02507323
Drug: ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A platelet aggregation inhibitor
Trial: NCT02507323
Drug: prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: a thienopyridine class inhibitor of platelet activation and aggregation
Trial: NCT04388761
Drug: Allogeneic adipose derived mesenchymal stem cells
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of Allogeneic adipose derived mesenchymal stem cells into the Kidney allograft
Trial: NCT00881738
Drug: Biaxin 250 mg Tablets (Abbott Laboratories, Inc, USA)
RxNorm normalized name: Biaxin 250 MG Oral Tablet
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00597402
Drug: Avastin
RxNorm normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avastin will be administered 10 mg/kg every other week beginning a minimum of 28 days after last major surgical procedure, open biopsy, or significant traumatic injury. Following completion of XRT, patients will receive treatment that includes 6 cycles of Avastin, beginning a minimum of 14 days after last XRT.
Trial: NCT00597402
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily temozolomide 75 mg/m2/day for 6.5 weeks of radiation treatment. Following completion of XRT, patients will receive treatment including temozolomide 200 mg/m2/day on the 1st 5 days of each 28-day cycle.
Trial: NCT00597402
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Following completion of XRT, patients will receive 6 cycles of treatment that includes irinotecan. Beginning a minimum of 14 days after last XRT, the irinotecan dose will depend on whether the patient is on enzyme-inducing antiepileptic drugs (EIAED). (EIAED:340 mg/m2 every other week, non-EIAED: 125 mg/m2.)
Trial: NCT05342558
Drug: Fluticasone Furoate/Vilanterol 100/25 mcgs
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dry powder inhaler with 30 blisters. 100/25mcgs a day for 24 weeks.
Trial: NCT05342558
Drug: Umeclidinium/Vilanterol 62.5/25 mcgs
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dry powder inhaler with 30 blisters. 62.5/25mcgs a day for 24 weeks
Trial: NCT05113511
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects received a single intravenous infusion (3 mg/kg) of bevacizumab for 90 minutes , and the volume of administration was calculated based on the subject's weight.
Trial: NCT00195936
Drug: Cinacalcet
RxNorm normalized name: Cinacalcet
DrugBank: Cinacalcet (DB01012)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single oral dose of Cinacalcet for children with Hypophosphatemic Rickets
Trial: NCT00239239
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: darbepoetin alfa SC dosing 0.45 mcg/kg 3 times per week through study day 40. Optional extended treatment period: 200 mcg Q2W through study day 110
Trial: NCT00674687
Drug: 2-weeks placebo then gabapentin
RxNorm normalized name: lacosamide
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo for 2 weeks followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 1 week
Trial: NCT01659359
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The samples were randomly allocated to use 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.
Trial: NCT02575755
Drug: Sulfadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01253642
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01253642
Drug: Phenelzine Sulfate
RxNorm normalized name: Phenelzine Sulfate
DrugBank: Phenelzine (DB00780)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02498301
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin will be provided to subjects either daily with placebo, or twice daily depending on which of the two experimental arms they are randomized to
Trial: NCT00436995
Drug: Darbepoetin Alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered IV or SC, Q2W at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200 or 300ug. Initial Q2W dose calculated from pre-enrollment QW doses. Doses titrated to achieve target Hb.
Trial: NCT03095079
Drug: recombinant human endostatin
RxNorm normalized name: Recombinant human endostatin
DrugBank: Endostatin (DB06423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin:dose was based on patient's weight and could be adjusted for weight change,75 mg/m\^2 by IV infusion separated in 3 different days Dacarbazine:250mg/m2,administered by intravenous (IV) infusion on the 1 to 5 day of each cycle~Hr-endostatin:dose based on body surface area as 15mg/m2,continuous intravenous infusion from day 1 to day 14
Trial: NCT01124188
Drug: Higher-dose venlafaxine
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosing of venlafaxine will range from 187.5-300 mg/day.
Trial: NCT02170324
Drug: Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00719459
Drug: Iron Sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venofer 20 mg/mL
Trial: NCT00719459
Drug: Iron Sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose 20 mg/mL
Trial: NCT01645098
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg/kg IV, additional doses of 0.5 mg/kg as needed
Trial: NCT01645098
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.5 mcg/kg/hr IV
Trial: NCT00740415
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: -Velcade®, 1,3 mg/m2 Intraveinous on days 1, 4, 8 and 11
Trial: NCT00740415
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: day - Dexamethasone, 40 mg Intraveinous
Trial: NCT00740415
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: -Day 1 and day 2 Bendamustine/Levact ®,, 90 mg/m2 Intraveinous
Trial: NCT03571191
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab will be administered at 120 mg per dose every 4 weeks for six months, with loading doses on days 8 and 15 of month 1.
Trial: NCT00552097
Drug: ezetimibe (plus simvastatin)
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral tablets; ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
Trial: NCT01860287
Drug: Buprenorphine 0.2 MG Sublingual Tablet
RxNorm normalized name: buprenorphine 0.2 MG Sublingual Tablet
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.2)
Trial: NCT02488980
Drug: Tafenoquine
RxNorm normalized name: tafenoquine
DrugBank: Tafenoquine (DB06608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tafenoquine 200 mg for three days followed by Tafenoquine 200 mg once a week for 24 weeks.
Trial: NCT01860287
Drug: Buprenorphine 0.4 MG Sublingual Tablet
RxNorm normalized name: buprenorphine 0.4 MG Sublingual Tablet
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.4)
Trial: NCT02495129
Drug: VAY736 lower dose
RxNorm normalized name: Calendula Flower
DrugBank: Calendula officinalis flower (DB14263)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a total number of 3 monthly subcutaneous injections with the lower dose of VAY736
Trial: NCT02488980
Drug: Mefloquine
RxNorm normalized name: Mefloquine
DrugBank: Mefloquine (DB00358)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefloquine 250 mg for three days followed by Mefloquine 250 mg once a week for 24 weeks.
Trial: NCT00029289
Drug: Lutein (10 or 30 mg/day) capsules
RxNorm normalized name: lutein
DrugBank: Lutein (DB00137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03764462
Drug: Raloxifene 60mg
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene 60mg tablet
Trial: NCT02211950
Drug: BI 44847
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04050059
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (5g tube Aspen pharma trading limited) will be applied topically in dose of 2.5 grams (half tube of cream) and area will be covered with tegaderm dressing. Application of EMLA will at least stay for 30 minutes before spinal needle insertion
Trial: NCT04050059
Drug: 2% lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In 2% lidocaine group infiltration (Xylocaine 2% Barrett Hodgson Pakistan Pvt limited), skin and subcutaneous tissue will be infiltrated with 3 ml of 2% lidocaine (dose of 60 mg) before spinal needle insertion
Trial: NCT03601260
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment of gout patients by oral dosage of 100 mg-300mg/ day of Allopurinol
Trial: NCT00379665
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg/ml at a dosage of approximately 2 mg per cubic cm of tumor. Weekly up to 6 injections.
Trial: NCT02211950
Drug: Acarbose
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04623255
Drug: OCTAPLAS
RxNorm normalized name: Octaplas A
DrugBank: Plasma protein fraction (human) (DB13968)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: plasma exchange
Trial: NCT02090673
Drug: Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02797717
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ARM A and ARM B
Trial: NCT02797717
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ARM B , 100mg/m2/day
Trial: NCT02797717
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ARM A and ARM B , 40mg/m2/day p.o
Trial: NCT02797717
Drug: Dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ARM A and ARM B , 250mg/m2 i.v
Trial: NCT00195624
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who relapse after initial response to alemtuzumab therapy will have cyclosporine added to the regimen after the 6 month visit. Dosing will be based on ideal body weight and will be adjusted to maintain a target level of 200 - 400 ng /ml.
Trial: NCT04001413
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab is an investigational drug in this study.
Trial: NCT00001499
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00001499
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04290039
Drug: Atropine Sulfate Ophthalmic Solution
RxNorm normalized name: Atropine Sulfate Ophthalmic Solution
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains active ingredient: atropine sulfate 10 mg equivalent to 8.3 mg of atropine. Inactive ingredients include benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate, edetate disodium, hypromellose (2910), monobasic sodium phosphate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection, USP.
Trial: NCT04290039
Drug: Atropine Sulphate Injection
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulfate injection, USP, 8mg/20mL (0.4 mg per mL) is a sterile, nonpyrogenic, isotonic, clear solution of atropine sulfate in water for injection with sodium chloride sufficient to render the solution isotonic. Each mL contains atropine sulfate, 0.4 mg; benzyl alcohol, 9 mg; sodium chloride 9 mg; and may contain sulfuric acid for pH adjustment, pH 3.5 (3.0 to 3.8).
Trial: NCT01478971
Drug: Epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available epoetin alfa administered weekly, twice weekly, or thrice weekly at an initial starting dose, frequency of administration, and mode of administration (intravenous \[IV\] or subcutaneous \[SC\]) individually determined for each participant using the site's usual standard of care. Subsequent dose adjustments or dose holds may have been made in order to maintain a hemoglobin concentration of \<11 g/dL.
Trial: NCT04528706
Drug: MIN-102
RxNorm normalized name: SBC-102
DrugBank: Sebelipase alfa (DB11563)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Once-daily dosing with a volume specified by the pharmacokineteic specialist to achive the desired plasma exposure. Min-102 Oral suspension, strength 15mg/ml.
Trial: NCT01162876
Drug: saxaglipitin
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration of 5 mg tablet before breakfast for 14 consecutive days
Trial: NCT04442919
Drug: Ticagrelor followed with Methoxyflurane
RxNorm normalized name: Methoxyflurane
DrugBank: Methoxyflurane (DB01028)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients who received ticagrelor followed with inhaled methoxyflurane due to unstable angina
Trial: NCT01478971
Drug: Peginesatide
RxNorm normalized name: Peginesatide
DrugBank: Peginesatide (DB08894)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as a once monthly intravenous (IV) or subcutaneous (SC) injection. The initial dose of peginesatide injection was based on the final weekly dose of epoetin administered in the SCP; subsequent doses may have been adjusted in order to maintain hemoglobin concentrations at \<11 g/dL.
Trial: NCT02981368
Drug: 18F-DCFPyL Injection
RxNorm normalized name: (18F)DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
Trial: NCT04442919
Drug: Ticagrelor followed with Morphine
RxNorm normalized name: Ticagrelor
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients who received ticagrelor followed with intravenous morphine due to unstable angina
Trial: NCT04442919
Drug: Ticagrelor alone
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients who received ticagrelor without any analgesia due to unstable angina
Trial: NCT01459588
Drug: Carboxymethylcellulose Based Eye Drop Formulation A
RxNorm normalized name: carboxymethylcellulose Ophthalmic Solution [EyS Dry Eye]
DrugBank: Carboxymethylcellulose (DB11059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboxymethylcellulose Based Eye Drop Formulation A (Refresh Optive® Advanced Sensitive Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
Trial: NCT01459588
Drug: Carboxymethylcellulose Based Eye Drop Formulation B
RxNorm normalized name: carboxymethylcellulose Ophthalmic Solution [EyS Dry Eye]
DrugBank: Carboxymethylcellulose (DB11059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboxymethylcellulose Based Eye Drop Formulation B (Refresh Optive® Advanced Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
Trial: NCT01459588
Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops
DrugBank: Carboxymethylcellulose (DB11059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (Optive® Sensitive Preservative-Free Lubricant Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
Trial: NCT01459588
Drug: Carboxymethylcellulose Based Lubricant Eye Drops
RxNorm normalized name: carboxymethylcellulose Ophthalmic Solution [Eyes Alive Lubricating]
DrugBank: Carboxymethylcellulose (DB11059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboxymethylcellulose Based Lubricant Eye Drops (Optive® Lubricant Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.